Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ELECTRA RCT
2024-518090-34-00Phase 3Completed
- Sponsor
- Nicolaus Copernicus University
- Start
- Nov 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of ticagrelor in acute coronary syndrome (ACS), myocardial infarction (MI), Non-ST-segment elevation myocardial infarction (NSTEMI) and 1 more (2 arms), sponsored by Nicolaus Copernicus University. Primary endpoint: BARC type 2, 3 or 5 bleeding within 12 months. Started Nov 2024; status: completed.
02
Drugs
ticagrelor
03
Conditions
acute coronary syndrome (ACS)myocardial infarction (MI)Non-ST-segment elevation myocardial infarction (NSTEMI)unstable angina
Beyond the preview
Go deeper on 2024-518090-34-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-518090-34-00.